Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2875
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine ; volume:5 ; number:1 ; day:08 ; month:10 ; year:2006 ; pages:1-5 ; date:12.2006
Malaria journal ; 5, Heft 1 (08.10.2006), 1-5, 12.2006
- Urheber
-
Meissner, Peter E.
- Beteiligte Personen und Organisationen
-
Mandi, Germain
Coulibaly, Boubacar
Witte, Steffen
Tapsoba, Théophile
Mansmann, Ulrich
Rengelshausen, Jens
Schiek, Wolfgang
Jahn, Albrecht
Walter-Sack, Ingeborg
Mikus, Gerd
Burhenne, Jürgen
Riedel, Klaus-Dieter
Schirmer, R Heiner
Kouyate, Bocar
Müller, Olaf
SpringerLink (Online service)
- DOI
-
10.1186/1475-2875-5-84
- URN
-
urn:nbn:de:1111-201608062901
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Meissner, Peter E.
- Mandi, Germain
- Coulibaly, Boubacar
- Witte, Steffen
- Tapsoba, Théophile
- Mansmann, Ulrich
- Rengelshausen, Jens
- Schiek, Wolfgang
- Jahn, Albrecht
- Walter-Sack, Ingeborg
- Mikus, Gerd
- Burhenne, Jürgen
- Riedel, Klaus-Dieter
- Schirmer, R Heiner
- Kouyate, Bocar
- Müller, Olaf
- SpringerLink (Online service)
Ähnliche Objekte (12)
Optimal dose‐finding for efficacy–safety models
Response-adaptive dose-finding under model uncertainty
Revisiting dose-finding of monoclonal antibodies in migraine
Dose-Finding Designs: The Role of Convergence Properties
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
Dose-finding studies in drug development for rare genetic diseases
Stereotactic body radiotherapy of adrenal metastases - a dose‐finding study
A multiple comparison procedure for dose‐finding trials with subpopulations
Stereotactic body radiotherapy of adrenal metastases — a dose‐finding study
Implementing the EffTox dose-finding design in the Matchpoint trial
Oral mannitol for bowel preparation: a dose-finding phase II study
A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies
Optimal dose‐finding for efficacy–safety models
Response-adaptive dose-finding under model uncertainty
Revisiting dose-finding of monoclonal antibodies in migraine
Dose-Finding Designs: The Role of Convergence Properties
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
Dose-finding studies in drug development for rare genetic diseases
Stereotactic body radiotherapy of adrenal metastases - a dose‐finding study
A multiple comparison procedure for dose‐finding trials with subpopulations
Stereotactic body radiotherapy of adrenal metastases — a dose‐finding study
Implementing the EffTox dose-finding design in the Matchpoint trial
Oral mannitol for bowel preparation: a dose-finding phase II study
A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies
Optimal dose‐finding for efficacy–safety models
Response-adaptive dose-finding under model uncertainty
Revisiting dose-finding of monoclonal antibodies in migraine
Dose-Finding Designs: The Role of Convergence Properties
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
Dose-finding studies in drug development for rare genetic diseases
Stereotactic body radiotherapy of adrenal metastases - a dose‐finding study
A multiple comparison procedure for dose‐finding trials with subpopulations
Stereotactic body radiotherapy of adrenal metastases — a dose‐finding study
Implementing the EffTox dose-finding design in the Matchpoint trial
Oral mannitol for bowel preparation: a dose-finding phase II study